A randomized study was carried out to compare the efficacy and adverse reactions of daily vs. alternate day regimens of amphotericin B in children with visceral leishmaniasis (VL). Six hundred and five children of VL below 14 years of age were randomized into two groups; Group A (302), who received amphotericin B at a dose of 1 mg kg À1 day À1 for 15 days and Group B (303); same doses but on alternate days. All patients in both groups were cured, who had completed course of amphotericin B therapy. None had relapsed at 1 and 6 months of follow-up. Adverse reactions in both groups were non-significant. The duration of stay and cost of therapy was significantly lower in Group A children who left the hospital against medical advice, which was also significantly more in Group B. Thus, daily regimen of amphotericin B is equally effective, well tolerated, not more toxic and cost-effective than alternate day regimen, which is currently practiced.
Introduction
Visceral leishmaniasis (VL) is a parasitic disease caused by Leishmania donovani and transmitted by Phlebotomus argentipes. VL is distributed worldwide and $12 million people are estimated to be infected with $5 00 000 new cases each year. Approximately 90% of the estimated new annual cases of VL occur in rural areas of India, Nepal, Bangladesh, Sudan and Brazil. In India, Bihar contributes $90% of estimated annual cases i.e. 200 000-250 000 new cases per year and 28 out of 37 districts are endemic and nearly 67.5 million people are at risk of disease [1, 2] . Approximately 50% of these patients are children. Furthermore, VL has emerged as opportunistic pathogens of HIV-infected children.
In recent years, treatment of VL is far from satisfactory due to increasing prevalence of resistance from pentavalent antimonials compound [sodium stibogluconate (SAG)]. In some studies, resistance to antimonial compounds reported have varied from 43 to 65% [3, 4] . On the other hand, treatment with miltefosine, an oral drug which is effective against VL, has a high rate of relapse and its availabilty as capsule in 10 and 50 mg, hence unsuitable for pediatric patients below age of 2 years. Although lipid formulations of amphotericin B are an important advancement in therapy with fewer doses required but their high cost precludes their use in poor rural children. Amphotericin B has been recommended as the drug of choice in doses of 0.5-1 mg kg À1 day À1 for at least 15 injections as infusion on alternate day by government of India in 2006 with intensive monitoring of cardiac status, electrolyte abnormalities, hepatic and renal functions. In alternate day therapy, patients require at least 33 days of admission in hospital for both investigation and treatment with at least two relatives per patient to look after. This causes great economic burden to poor children with VL [3, 5] . Therefore, this study was planned with the objectives of feasible daily intravenous dosage of amphotericin B with their efficacy, adverse events and cost-effectiveness in children with VL.
Materials and Methods
The authors undertook a prospective, randomized study of amphotericin B therapy in children with VL. The study was conducted in parallel at children ward of Nalanda Medical College and child care center, Patna. Ethics committees of the medical college and child care center approved study protocol and consent form. Written informed consent was taken from legal guardians of children.
A total of 605 patients aged 1-14 years of VL, who was diagnosed based on compatible clinical features and presence of L. donovani bodies in bone marrow aspirates were enrolled in the study. They were randomized into two treatment groups, Groups A and B by electronically generated random ).
Children with bleeding diathesis, liver disorder [alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >3 times, serum bilirubin >2 times of normal], renal dysfunction [Blood urea nitrogen (BUN) and serum creatinine, 1.5 times of normal], co-existing malaria or HIV, neutrophil count <1000 mm À3 and platelet count less than 40 000 mm À3 were excluded from study. Patients who had received incomplete course of SAG were also excluded from study.
All patients were monitored for adverse events, hematological variables, serum chemistry and splenic size below left costal margin. The parasitological analyses of bone marrow aspirates were performed at completion of therapy, 1 month and at 6 months. The density of parasites was graded from 0 (no parasite/1000 high power field) to 6 (>100 parasites/field).
The cure was defined as an absence of parasites at the end of therapy and no relapse during 6 months of follow-up. Relapse was defined by appearance of symptoms and signs suggestive of leishmaniasis with demonstrable L. donovani (LD) bodies in bone marrow aspirates after initial cure. Treatment failure was defined as either the lack of initial cure or relapse.
Parents were interviewed at completion of therapy for total expenses done by them on stay (lodging, meals, snacks, tea, etc.) in terms of Indian rupees excluding the cost of drug.
Statistical analysis
The data was analyzed by SPSS version.10.software. Student's t-test and z-test were used to test the significance of difference between two means and proportions, respectively. Table 1 showed the basic characteristics of the two groups of patients. Both groups were comparable in term of age, splenic size and hemoglobin level. The duration of illness and total leukocyte count are significantly higher and lower, respectively, in Group A as compared with Group B.
Results
Out of 302 children in Group A and 303 in Group B, 300 and 270 children completed treatment, respectively, which was significantly higher in Group A. There was regression in size of spleen in both groups at completion of therapy and all patients achieved parasitological cure in both groups at the end of treatment. One patient in Group A and three patients in Group B had lost to follow-up. None of patients (299 in Group A and 267 in Group B) had relapsed in follow-up at 1 month and 6 months. Hence definitive cure at 6 months was significantly higher in Group A, i.e. those who received daily intravenous amphotericin B therapy ( Table 2) .
The difference in adverse reactions associated with amphotericicn B therapy between two groups were not significant. Shivering and fever occurred in 500/ 4810 (10.39%) infusions in Group A as compared with Group B; 577/4500 (12.82%). The adverse reactions occurred mostly in first week but some had continued severe reaction even after the end of infusion. One patient in Group A and three patients in Group B were terminated from treatment due to severe adverse reactions. Fifteen patients of Group A and 12 of Group B had elevated serum creatinine during treatment and required temporary withdrawal of drug for 7 days. Two patients in Group A and one patient in Group B were excluded from study because serum creatinine was >3 mg dl À1 , which did not normalize despite cessation of drug for 7 days. In Group B, 28 patientswith a significantly much higher serum creatinine (p < 0.0001) had left against medical advice probably because of longer treatment period and financial reasons ( Table 3 ). The mean expenditure of one attendant per patient is significantly much lower in Group A as compared with Group B (p < 0.0001).
Discussion
Amphotericin B is highly effective and reasonably safe drug in comparison to SAG. The present study was done to find out efficacy, adverse events and cost-effectiveness of daily vs. alternate day infusion of amphotericin B in children suffering from VL. The number of patients who completed treatment and definitive cure achieved at 6 months were significantly higher in children, who received daily intravenous infusion. The number of episodes of shivering, rigor and fever related to intravenous infusion were almost similar in both groups. The severe adverse events related to infusion are non-significant, whereas number of patients who had left against medical advice is significantly higher in Group B. This may be due to prolonged duration of therapy and cost of boarding and lodging.
This study also revealed that renal function derangement associated with intravenous infusion of amphotericin B is also non-significant among both groups. Thakur et al. [5] in their study in patients including both adult and children with VL also reported that daily amphotericin therapy is equally effective, not more toxic, equally tolerable and much more cost-effective than alternate day therapy. Another study by Sunder et al. [6] involving both children and adults on 1578 subjects reported that daily treatment with amphotericin B is efficient and effective for VL in India. But none of study had taken exclusively children suffering from VL. Probably this is the first study exclusively in children regarding daily vs. alternate day intravenous infusion of amphotericin B.
In our study, the mean expenditure of each attendant per patient is also significantly higher in Group B during hospital stay as compared with Group A. This excludes loss of daily wages earned by attendant while stay in hospital. Thus, the duration of stay in hospital with economic burden associated with alternate day intravenous infusion therapy can be minimized by daily intravenous doses.
In conclusion, it is to be stated that our data also suggest the daily dose of 1 mg kg À1 day À1 regimen is equally effective, not more toxic, costeffective and well tolerated as alternate day regimen of same dose. Therefore, it should be preferred to treat VL.
